Protagonist Therapeutics, Inc (PTGX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$143.65

From 52W high−9.85%

Volume1.78M

Market cap$9.25B

P/E (TTM)117.4x

P/S (TTM)32.8x

Div yield—

Key dataSep 18, 2026

Open

$143.65

From 52W high

−9.85%

Volume

1.78M

Market cap

$9.25B

ValuationView details →

P/E (Fwd)

71.4x

EV/EBITDA

99.2x

P/E (TTM)

117.4x

RSI (14)

45.3

MomentumView details →

1D Return

−0.49%

YTD Return

+63.80%

SummaryUpdated Jun 1, 2026

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Newark, California. The company went public in August 2016 and specializes in discovering and developing peptide-based therapeutic drugs targeting hematology, blood disorders, and inflammatory diseases. Protagonist has evolved from a research-focused biotech startup into a company with multiple clinical-stage programs and strategic partnerships, including a significant collaboration with Janssen Biotech.

Ask drillr about Protagonist Therapeutics, Inc →

ValuationView details →

P/E (Fwd)

71.4x

P/E (TTM)

117.4x

EV/EBITDA

99.2x

EV/Sales

30.1x

P/S (TTM)

32.8x

P/B (TTM)

11.0x

ProfitabilityView details →

Gross Margin

99.86%

Net Margin

29.40%

EBITDA Margin

30.31%

ROE (TTM)

9.85%

ROA (TTM)

9.36%

Asset Turnover

0.36x

GrowthView details →

Revenue YoY

+34.81%

EPS YoY

+46.76%

FCF YoY

+256.27%

Revenue CAGR 3Y

+20.07%

EPS CAGR 3Y

—

EBITDA YoY

+109.52%

MomentumView details →

1D Return

−0.49%

YTD Return

+63.80%

1Y Return

+130.01%

RSI (14)

45.3

vs 50D SMA

−0.40%

vs 200D SMA

+31.64%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

21.71x

Quick Ratio

21.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$2.29

EPS Surprise

0.88%

Beats (12Q)

8/12

Next Q EPS Est

$2.43

Avg Surprise (4Q)

825.87%

Rev Surprise

0.68%

Financials snapshotView financials →

Revenue (TTM)

281.99M

Net Income (TTM)

82.91M

Op. CF (TTM)

131.20M

Next earningsNov 5, 2026 →

Latest newsMore news →

Protagonist Therapeutics announced a share repurchase program authorizing up to $300 million of its common stock, funded from cash and collaboration payments.12d ago

Similar companies

Everest Medicines Limited01952.HK 热景生物688068.SH Abivax S.A.ABVX Arrowhead Pharmaceuticals, Inc.ARWR GenFleet Therapeutics (Shanghai) Inc.02595.HK Suzhou Ribo Life Science Co06938.HK Find similar companies →

Latest newsMore news →

Protagonist Therapeutics President and CEO Dinesh V. Patel sold 124,000 shares of the company's common stock for approximately $18.2 million between September 8 and September 10, 2026, under a pre-arranged 10b5-1 trading plan.9d ago Protagonist Therapeutics announced a share repurchase program authorizing up to $300 million of its common stock, funded from cash and collaboration payments.12d ago